IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study | Zendy

Sarah Shalhoub | Zendy; Fayssal Farahat | Zendy; Abdullah Mohammed Y Al-Jiffri | Zendy; Raed Simhairi | Zendy; Omar Shamma | Zendy; Nauman Siddiqi | Zendy; Adnan Mushtaq | Zendy

Open Access

IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

Author(s) -

Sarah Shalhoub,

Fayssal Farahat,

Abdullah Mohammed Y Al-Jiffri,

Raed Simhairi,

Omar Shamma,

Nauman Siddiqi,

Adnan Mushtaq

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv085

Subject(s) - medicine , ribavirin , middle east respiratory syndrome coronavirus , mortality rate , pneumonia , gastroenterology , diabetes mellitus , retrospective cohort study , viral load , immunology , covid-19 , virus , disease , endocrinology , hepatitis c virus , infectious disease (medical specialty)

Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant mortality. We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research